Stephen Edward Rapecki

USPTO Granted Patents = 27 (Patent Applications = 17)

CIPO Patents = 6 (Patent Applications = 8)

EPO Patents = 13 (Patent Applications = 24)

Average Co-Inventor Count = 3.8

ph-index = 7

Forward Citations = 128(Granted Patents)

Location History:

Burnham, GB (2011 - 2012)
Berkshire, GB (2013 - 2018)
Slough Berkshire, GB (2020)
Slough, GB (2011 - 2023)

Company Filing History:

Years Active: 2011-2025

Loading Chart...

27 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12331117 - Antibody molecules which bind CD22 (2025-06-17),

2. 11692041 - Antibody molecules which bind CD45 (2023-07-04),

3. 11674967 - Method of identifying potential inhibitors of APO TNFα trimers (2023-06-13),

4. 11472879 - Antibody molecules which bind CD22 (2022-10-18),

5. 11466324 - Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy (2022-10-11),

6. 11448655 - Method for identifying a modulator of the TNFα or CD40L interaction with their cognate receptors (2022-09-20),

7. 11261252 - Molecules with specificity for CD79 and CD22 (2022-03-01),

8. 10883996 - Methods of identifying signaling modulators of the trimeric TNFa (2021-01-05),

9. 10829566 - Method employing bispecific antibodies (2020-11-10),

10. 10775385 - Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers (2020-09-15),

11. 10774152 - Molecules with specificity for CD45 and CD79 (2020-09-15),

12. 10705094 - TNF receptor signaling modulator assay (2020-07-07),

13. 10618957 - Antibody molecules which bind CD79 (2020-04-14),

14. 10590197 - Antibody molecules which bind CD22 (2020-03-17),

15. 10370447 - Molecules with specificity for CD79 and CD22 (2019-08-06),

Title: Stephen Edward Rapecki: Innovator in Antibody Therapeutics

Introduction

Stephen Edward Rapecki is a prominent inventor based in Slough, GB, recognized for his contributions to the field of antibody therapeutics. With an impressive portfolio of 26 patents, Rapecki has made significant advancements in medical research and treatment technologies.

Latest Patents

Rapecki's latest innovations include groundbreaking work on antibody molecules that specifically bind to CD45. This invention comprises constructs that offer promising applications in pharmaceutical compositions aimed at treatment strategies. Another significant patent involves a method for identifying potential inhibitors of the APO TNFα trimers. This patent details a stable trimeric TNFα structure that binds to the TNFR1 receptor, providing potential therapeutic effects for diseases related to soluble TNFα/TNFR1 interactions without increasing risks associated with membrane-bound TNFα signaling.

Career Highlights

Throughout his career, Rapecki has collaborated with renowned companies in the pharmaceutical sector, including UCB Biopharma and UCB Pharma. His role in these organizations has helped to further research and development in antibody therapies, significantly impacting patient care.

Collaborations

In his journey, Rapecki has worked alongside notable colleagues such as Ralph Adams and Andrew George Popplewell. These collaborations have undoubtedly contributed to his success and the innovative breakthroughs they have achieved collectively.

Conclusion

Stephen Edward Rapecki continues to be a key player in the field of antibody therapeutics, with a strong focus on developing innovative solutions to complex medical challenges. His patents signify not only his inventive prowess but also his commitment to advancing healthcare through scientific innovation.

This text is generated by artificial intelligence and may not be accurate.